Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
INTRODUCTION
Neurofibromatosis Type 2 (NF2), a genetic disorder with highly penetrant autosomal dominant transmission, is characterized by the predictable development of bilateral vestibular schwannomas (VS), intracranial and spinal schwannomas, meningiomas, gliomas and ependymomas, cataracts and multiple skin tumors. Tumor progression, as well as therapeutic intervention, may lead to significant cranial, spinal and peripheral nerve dysfunction, resulting in global impairment across of variety of domains. Currently, ideal management of NF2 disease is challenging, complex and controversial. International consensus recommendations and expert panels have described the importance of quality of life (QoL) measurements in clinical decision making and research trials. At present, however, there are few studies examining the QoL in patients with neurofibromatosis and NF2-specific, validated metrics for this population are not widely available.
The aim of the current study is to develop, refine and validate a multi-dimensional metric for assessment of QoL in patients with NF2.
BODY
Research accomplishments as well as challenges encountered in methodology are described in detail below and are based on the previously outlined Statement of Work (SOW). Task 1 of the SOW involved the development of a NF2-specific QoL module. Task 1A involved generation of an exhaustive list of NF2-specific QoL issues and assessment of content validity using the following methods:
literature review of existing QoL metrics
(ii) structured interviews with members of multidisciplinary NYU Neurofibromatosis Center (iii) structured patient interviews with NF2 patients (iv) Operationalization of content into a set of questionnaire items using the EORTC item bank and generation of novel items.
Complete bibliography of the literature review is included in Appendix A. As described previously, research examining QoL in NF2 patients is currently lacking. NF2 is a genetic disorder with highly penetrant autosomal dominant transmission that characterized by the predictable development of bilateral vestibular schwannomas (VS), intracranial and spinal schwannomas, meningiomas, gliomas and ependymomas, cataracts and multiple skin tumors. Tumor progression, as well as therapeutic intervention, may lead to significant cranial, spinal and peripheral nerve dysfunction. The unique complexity of the intra-cranial and extra-axial tumor burden in this population leads to a diverse constellation of symptoms and impairments across a wide variety of functional domains. Therefore, a systematic literature review was performed targeting QoL metrics applied to patient populations with brain, skull base, intracranial, spinal, ocular, or head and neck disease.
Additionally, given the eventual development of profound sensorineural hearing loss in this population, research examining QoL metrics in populations with deafness as well as those receiving auditory brainstem implants were included. Lastly, studies investigating QoL in patients with genetic diseases affecting reproduction and family planning were also reviewed.
Literature search was performed using PUBMED and MEDLINE. Relevant articles were reviewed for additional references and then systematically categorized by affected organ system, ie brain, skull base, intracranial, spinal, ocular, and head and neck disease (Appendix A.) A preliminary list of QoL domains applicable to patients with NF2 was generated and used in the structured interview portion of the module development.
Structured interviews were performed with patients with NF2 (Appendix B) and members of multidisciplinary NYU Neurofibromatosis Center (Appendix C). Interviews followed the guidelines outlined in the EORTC Guidelines for Module Development 1 and included both open-ended and semi-structured questions.
Interviews lasted 30 minutes -1 hour. Notes were taken throughout the interviews and were clarified with the interviewee at the end of the session, if necessary.
Structured interviews of patients are detailed in Appendix B and consisted of 3 parts: general, relevance of domains and breadth of coverage. Patients were asked to identify and rank 5 domains which they valued particularly highly and those in which they experienced significant challenges. Neutral probes were used to obtain more specific details about each experience. Open-ended questions were used to query the patients regarding breadth of identified QoL domains as well as additional issues missing or incompletely addressed in the provided list.
Structured interviews of health care providers are detailed in Appendix C and similarly consisted of 3 parts: relevance of domains, relative importance within each domain and breadth of coverage. Providers were asked to rate each domains on a 4-point Likert scale from (1) "not at all relevant" to (4) "very relevant." For instances in which the individual responded with a (1) "not at all relevant," additional follow-up questions were asked to clarify the basis of the response. To identify which issues affect NF2 patients most profoundly, providers were asked to identify and rank the top 5 domains they felt had the greatest impact on QoL in NF2.
For assessment of the relative importance of each issue (and ultimately pare down the QoL questionnaire), providers were asked to indicate whether each item should be included on the final questionnaire. Lastly, providers were asked to identify additional issues that were missing or incompletely addressed in the list.
Once completed, responses were analyzed for deletion or addition of issues. Domains were considered for deletion if they 1) were not included in the top 5 of any patient responses to challenges or positive experiences; 2) were not included in the top 5 of any provider response; or 3) had a low mean relevance score (mean < 2) in provider evaluation. New areas were considered for addition if 1) they were mentioned by at least 2 patients or providers or 2) mentioned by 1 patient or provider with significant plausible motivation.
To date, interviews with both patients and providers are ongoing. Among patients interviewed thus far (N=5), areas of hearing, balance/ambulation and oral intake have the highest rank order for importance, while hearing, balance/ambulation and facial weakness represent the areas with highest rank for difficulty. For breadth of coverage, 2 patients noted difficulty related to writing or typing due to peripheral neurofibromas.
Additionally, 2 suggested that internet based survey (rather than a paper format) would be an easier format to complete given their level of functioning. Among provider responses, hearing, balance/ambulation and facial weakness have the highest rank order and mean relevance score (4.0). Areas with low relevance score (2-3)
include sexual activity and future uncertainty. No area has yet received a relevance score of 1.
Following completion of structured interviews, items will be added or deleted based on the guidelines above. This will then be refined into provisional module and pre-tested to a small group of patients. All patients will be de-briefed following pre-testing using a structured interview (Appendix D.) 
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